ABVX vs JAGX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and JAGX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and JAGX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.

Full ABVX guide

Jaguar Health, through its Napo Pharmaceuticals subsidiary, is a commercial-stage company centered on crofelemer, a plant-derived compound sourced from the Croton lechleri tree. Its approved human product, Mytesi, treats noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also has an animal-health arm, including Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and it markets Gelclair for oral mucositis. In January 2026 Jaguar out-licensed US marketing rights for Mytesi and Canalevia-CA1 to Woodward Specialty, an affiliate of privately held Future Pak, in a deal worth up to $38 million (roughly $18 million upfront plus milestones). Future Pak became the exclusive US marketer while Jaguar stays the manufacturer, giving Jaguar non-dilutive capital and letting it concentrate crofelemer development on human rare-disease indications such as intestinal failure and short bowel syndrome.

Full JAGX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
• JAGX drivers: Future Pak license and non-dilutive cash; Crofelemer rare-disease pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For JAGX, the dominant risks are financing and dilution.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; JAGX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and JAGX guides.

ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

JAGX. Figures are approximate, tied to the asOf date, and distorted by one-time items and the recent reverse split, so standard valuation multiples are not very meaningful here. The Q1 2026 profit came from a one-time license fee, not sustainable operations, and per-share figures are hard to compare across reverse splits. Treat any headline number with caution and verify live data before acting; this is a speculative micro-cap where the balance sheet and financing runway matter far more than reported earnings.

Headline figures (approximate, July 2026): ABVX shows market cap ~$7-8B, product revenue (ttm) ~negligible (pre-commercial), net loss (fy2025) ~EUR 336M, r&d expense (fy2025) ~EUR 178M; JAGX shows q1 2026 revenue ~$20.3 million, but almost entirely a one-time ~$19 million license fee, not recurring sales, recurring product revenue (q1 2026) ~$1.2 million for prescription products (Mytesi, Gelclair, Canalevia-CA1), q1 2026 net income ~$8.7 million, driven by the license fee rather than operations; net loss to common shareholders narrowed to ~$7.0 million, market capitalization Micro-cap, roughly low single-digit millions in mid-2026 (verify live before acting).

ABVX and JAGX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and JAGX exposure against your real portfolio. It is not an investment adviser.